STOCK TITAN
  1. Home
  2. Sec-filings
  3. HAE
  4. [8-K] HAEMONETICS CORP Reports Material Event

Haemonetics (NYSE: HAE) director Dockendorff to leave board after 2026 meeting

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Haemonetics Corporation reports that long-serving director Charles J. Dockendorff has informed the company he will not stand for re-election at its 2026 Annual Meeting of Shareholders. He has served on the Board since 2014 and is a member of the Audit Committee and the Governance and Compliance Committee.

Mr. Dockendorff will continue as a director and in his committee roles until the 2026 Annual Meeting. The company states that his decision not to stand for re-election is not the result of any disagreement with Haemonetics.

Positive

  • None.

Negative

  • None.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Par value per share $0.01 per share Common stock par value disclosed in listing information
Notification date April 27, 2026 Date Dockendorff informed Haemonetics he will not stand for re-election
Board service start 2014 Year Charles J. Dockendorff joined the Haemonetics Board
Signature date May 1, 2026 Date the Form 8-K was signed by the President and CEO
Annual Meeting of Shareholders financial
"he will not stand for re-election at the Company’s 2026 Annual Meeting of Shareholders"
A yearly gathering where a company’s owners (shareholders) vote on key items like electing the board, approving executive pay, and ratifying auditors, and receive updates on performance and strategy. Think of it as an annual town hall for owners: it matters to investors because outcomes and disclosures can affect leadership, corporate direction, dividend and governance policies, and therefore the company’s risk and potential return.
Audit Committee financial
"currently serves as a member of the Audit Committee and the Governance and Compliance Committee"
A company's audit committee is a small group of board members who act like independent inspectors for the firm's finances, overseeing how financial reports are prepared, monitoring internal controls, and managing the relationship with external auditors. Investors care because a strong audit committee reduces the risk of accounting errors, fraud, or misleading statements, making financial statements more trustworthy and helping protect shareholder value.
Governance and Compliance Committee financial
"currently serves as a member of the Audit Committee and the Governance and Compliance Committee"
Emerging Growth Company regulatory
"405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging Growth Company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Understanding 8-K Material Events →
0000313143false00003131432026-04-272026-04-27

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 27, 2026

HAEMONETICS CORPORATION
(Exact name of registrant as specified in its charter)
Massachusetts001-1404104-2882273
(State or other jurisdiction
of incorporation)
(Commission File Number)
(I.R.S. Employer
Identification No.)

125 Summer Street
Boston, MA 02110
(Address of principal executive offices, including zip code)
Registrant’s telephone number, including area code: 781-848-7100
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common stock, $.01 par value per shareHAENew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging Growth Company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐







Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On April 27, 2026, Charles J. Dockendorff informed Haemonetics Corporation (the “Company”) that he will not stand for re-election at the Company’s 2026 Annual Meeting of Shareholders (the “2026 Annual Meeting”). Mr. Dockendorff has served as a member of the Board of Directors (the “Board”) of the Company since 2014 and currently serves as a member of the Audit Committee and the Governance and Compliance Committee. Mr. Dockendorff will continue to serve as a director and in his committee roles until the 2026 Annual Meeting. Mr. Dockendorff’s decision not to stand for re-election at the 2026 Annual Meeting is not the result of any disagreement with the Company.




SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
HAEMONETICS CORPORATION
May 1, 2026By:/s/ Christopher A. Simon
Name:Christopher A. Simon
Title:President and Chief Executive Officer


Source: View Original Filing on SEC EDGAR

FAQ

What did Haemonetics Corporation (HAE) announce in this Form 8-K?

Haemonetics announced that director Charles J. Dockendorff informed the company he will not stand for re-election at its 2026 Annual Meeting of Shareholders, while continuing to serve on the Board and committees until that meeting.

When will Charles J. Dockendorff leave the Haemonetics (HAE) Board?

Charles J. Dockendorff will remain a director and committee member until Haemonetics’ 2026 Annual Meeting of Shareholders. After that meeting, he will no longer serve on the Board because he is not standing for re-election.

Why is Haemonetics director Charles J. Dockendorff not standing for re-election?

Haemonetics states that Charles J. Dockendorff’s decision not to stand for re-election at the 2026 Annual Meeting is not the result of any disagreement with the company, indicating no disclosed dispute over policies, practices, or governance.

What roles does Charles J. Dockendorff hold at Haemonetics (HAE) until the 2026 meeting?

Until the 2026 Annual Meeting, Charles J. Dockendorff will continue serving as a member of the Haemonetics Board of Directors, the Audit Committee, and the Governance and Compliance Committee, maintaining his existing governance responsibilities.

How long has Charles J. Dockendorff served on the Haemonetics Board?

Charles J. Dockendorff has served as a member of Haemonetics’ Board of Directors since 2014, giving him more than a decade of board service by the time of the 2026 Annual Meeting of Shareholders.

Filing Exhibits & Attachments

3 documents

Other Documents